Colonic purgative tablet and colonic purgative comprising same
The alginate-coated colon laxative tablet addresses gastric mucosa damage and compliance issues by using alginate as a gel-forming coating with osmotic substances, achieving effective bowel cleansing and improved patient experience during colonoscopy preparation.
Patent Information
- Application Number
- PCT/KR2024/006414
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Conventional colon laxatives face issues such as gastric mucosa damage, unpleasant taste, high dosage burden, and poor medication compliance due to their formulation and mechanism of action, which affect their efficacy and patient experience during colonoscopy preparation.
A colon laxative tablet with a gel-forming coating layer containing alginate as the main ingredient, combined with osmotic substances like anhydrous sodium sulfate, potassium sulfate, and simethicone, designed to prevent gastric mucosa damage and ensure effective bowel cleansing at a smaller dose, while improving compliance through a packaging bag format.
The alginate-coated tablet effectively prevents gastric mucosa damage, ensures quick disintegration, and provides excellent bowel cleansing with improved medication compliance, as demonstrated by clinical trial results showing non-inferiority to existing preparations in terms of cleanliness and safety.
Smart Images

Figure KR2024006414_21112024_PF_FP_ABST
Abstract
Description
Colon laxative tablets and colon laxatives containing the same
[0001] The present invention relates to a colonic laxative tablet and a colonic laxative comprising the same, and more specifically, to a colonic laxative tablet comprising a gel-forming coating layer comprising alginate as a main component, which prevents damage to the gastric mucosa and has an excellent intestinal cleansing effect, and a colonic laxative comprising the same.
[0002] Colon cleansing is required to maximize the effectiveness of colonoscopy. This is achieved by adjusting the diet and taking laxatives before the procedure.
[0003] Drugs used as colonic laxatives are categorized as osmotic laxatives, stimulant laxatives, and saline laxatives based on their mechanism of action. Osmotic laxatives are non-absorbable electrolyte solutions that, after administration, create an osmotic pressure gradient within the intestines, washing away feces. Stimulant laxatives interfere with the absorption of water and electrolytes in the colon and stimulate the intestinal mucosa, inducing colonic muscle contractions and forcing defecation. Saline laxatives are not absorbed in the intestines but instead retain water in the small intestine through osmotic pressure, softening the stool while simultaneously stimulating peristalsis to promote defecation.
[0004] An example of an osmotic laxative is a polyethylene glycol (PEG) solution. PEG has minimal impact on plasma volume and electrolyte balance, making it suitable for patients with underlying conditions such as kidney, heart, and liver disease. However, it requires a large volume of solution (4 liters) and has a rather unpleasant taste, leading to low compliance. There are also products that combine PEG and ascorbic acid and provide a cleansing effect with just 2 liters, but the characteristic strong taste of PEG still makes the dosage burdensome.
[0005] Examples of stimulant laxatives include a combination of sodium picosulfate, magnesium oxide, and citrate. Adults should take 170 ml of this solution before 8:00 AM the day before the test, followed by an additional 170 ml 6-8 hours later. This significantly reduces the dosage compared to PEG preparations. However, since it is recommended to drink 250 ml of water per hour after taking the laxative to avoid dehydration, compliance remains limited.
[0006] Examples of saline laxatives include sodium phosphate and sulfate. Phosphate has been reported to have a bowel cleansing effect at lower doses than PEG, but it also causes side effects such as abdominal distension, pain, and dizziness at a similar frequency to PEG. In particular, it has been found to cause complications such as acute phosphate nephropathy, leading the European Society of Gastroenterology to restrict the use of oral sodium phosphate in 2013. In contrast, sulfate is considered relatively safer than phosphate. Sulfate preparations are mainly composed of sodium sulfate, potassium sulfate, and a combination of sodium sulfate.
[0007] Korean Patent Publication No. 10-2015-0089430 discloses a laxative tablet made by mixing magnesium sulfate, potassium sulfate, and sodium sulfate with PEG as an excipient rather than a main ingredient, then adding sodium stearyl fumarate and mixing the mixture, and then compressing the tablet using a tablet press. The document states that a product composed of the three sulfate salts of magnesium sulfate, potassium sulfate, and sodium sulfate has been reported to be safe and effective, and that this led to the development of a product called the Suprep Bowel Prep Kit in the United States. Products composed of the three sulfate salts above are also available in Korea, such as Suprep Liquid and Suclear Liquid. However, liquid preparations have the problem of low medication compliance due to the salty taste and strong odor characteristic of sulfate salts. In order to eliminate the characteristic rotten egg odor of sulfate salts, excessive sweeteners and flavorings are sometimes added, but the effect is limited.
[0008] In order to solve the problems of the conventional colonic laxatives as described above, the present applicant proposed a solid formulation of a colonic laxative containing the main ingredients anhydrous magnesium sulfate, potassium sulfate, anhydrous sodium sulfate, and simethicone through Korean Patent Publication No. 10-2019-0041233. The colonic laxative according to the document is commercially available under the name Orapang Tablet. Orapang Tablet has various advantages such as increased medication compliance and excellent bowel cleansing effect. However, after the commercialization of Orapang Tablet, some patients have reported cases of gastric mucosal damage and discomfort in swallowing due to the large size of the tablet. Therefore, there is a need to develop a colonic laxative that can solve these problems while also having an excellent bowel cleansing effect.
[0009] The present invention aims to provide a colonic laxative tablet that can prevent damage to the gastric mucosa due to physical collision between the tablet and the gastric mucosa by introducing a gel-forming coating layer containing alginate as a main component into a tablet containing an osmotic substance, while allowing the osmotic substance contained in the tablet to rapidly disintegrate, thereby providing an excellent intestinal cleansing effect even at a small dosage.
[0010] The present invention also aims to provide a colon laxative that can be conveniently taken through a packaging bag.
[0011] The present invention relates to a colonic laxative tablet comprising: a tablet comprising an osmotic substance, simethicone, and a water-soluble binder; and a gel-forming coating layer formed on the tablet comprising alginate as a main component; wherein the osmotic substance comprises at least one selected from the group consisting of anhydrous sodium sulfate, potassium sulfate, anhydrous magnesium sulfate, sodium sulfate hydrate, magnesium sulfate hydrate, sodium picosulfate hydrate, light magnesium oxide, citric acid, polyethylene glycol, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate, sodium bicarbonate, anhydrous sodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate, magnesium oxide, and potassium sulfate; and comprising at least 50 wt% of the alginate based on the total weight of the gel-forming coating layer.
[0012] In one embodiment, the osmotic agent may include anhydrous sodium sulfate, potassium sulfate, and anhydrous magnesium sulfate.
[0013] In one embodiment, the colon laxative tablet may contain 60 to 90 parts by weight of anhydrous sodium sulfate, 5 to 25 parts by weight of potassium sulfate, and 1 to 15 parts by weight of anhydrous magnesium sulfate, per 100 parts by weight of the osmotic substance.
[0014] In one embodiment, the colonic laxative tablet may contain 0.1 to 2 parts by weight of simethicone and 0.5 to 20 parts by weight of a water-soluble binder per 100 parts by weight of the osmotic substance.
[0015] In one embodiment, the water-soluble binder may be at least one selected from the group consisting of copovidone, polyethylene glycol, and povidone.
[0016] In one embodiment, the alginate may be at least one selected from the group consisting of sodium alginate, potassium alginate, and magnesium alginate.
[0017] In one embodiment, the gel-forming coating layer may further comprise an adhesion improving agent.
[0018] In one embodiment, the adhesive improver may be at least one selected from the group consisting of polyvinyl alcohol-polyethylene glycol graft copolymer, hypromellose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyol, gelatin, carboxymethyl cellulose, and povidone.
[0019] In one embodiment, the gel-forming coating layer may further comprise a mucosal protective agent.
[0020] In one embodiment, the mucosal protective agent may be at least one selected from the group consisting of ecabet sodium hydrate, irsogladin maleate, and polarprezinc.
[0021] In one embodiment, the colon laxative tablet may further include an adhesive improving coating layer comprising an adhesive improving agent as a main component on the gel forming coating layer.
[0022] In one embodiment, the colon laxative tablet may contain at least 50 wt% of the adhesive improving agent based on the total weight of the adhesive improving coating layer.
[0023] In one embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution having a pH of 2 or lower according to the second dissolution test method, the osmotic substance can be dissolved at 30 wt% or less within 5 minutes.
[0024] In one embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution having a pH of 3.5 to 5.5 according to the second dissolution test method, the osmotic substance can be dissolved by 30% or more by weight within 5 minutes.
[0025] In one embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution of pH 6 to 8.5 according to the second dissolution test method, the osmotic substance can be dissolved by 40 wt% or more within 5 minutes.
[0026] The present invention also provides a colon laxative comprising two or more packaging bags each containing two or more colon laxative tablets, and taking the colon laxative tablets contained in one of the packaging bags at a time.
[0027] The present invention may also relate to a pharmaceutical composition for a colon laxative, wherein the patient takes 160 colon laxative tablets and 425 ml of water on the day before a colonoscopy, then takes 850 ml of water twice in 425 ml portions, and on the day of the examination, the colon laxative tablets and water are taken repeatedly in the same manner as above, and the total dosage of the colon laxative is 38 to 55 g.
[0028] The present invention may also relate to a pharmaceutical composition for a colonic laxative, wherein on the day of a colonoscopy, 160 colonic laxative tablets according to the above and 425 ml of water are taken, and then 850 ml of water is taken in two additional doses of 425 ml each, repeating this twice, and the total dosage of the colonic laxative is 38 to 55 g.
[0029] The present invention provides a colonic laxative tablet having an excellent intestinal cleansing effect by introducing a gel-forming coating layer containing alginate as a main component into a tablet containing an osmotic substance, thereby preventing damage to the gastric mucosa due to physical collision between the tablet and the gastric mucosa, while allowing the osmotic substance contained in the tablet to rapidly disintegrate. The colonic laxative tablet according to the present invention can exhibit an excellent intestinal cleansing effect even with a small dosage, and can further improve medication compliance by optionally miniaturizing the tablet or introducing an adhesive-improving coating layer.
[0030] The present invention also provides a colon laxative that can be conveniently taken through a packaging bag.
[0031] The effects of the present invention are not limited to the above-described effects, and should be understood to include all effects that can be inferred from the composition of the invention described in the description or claims of the present invention.
[0032] Figure 1 is an image of the gelation of the tablet of Example 1 in a solution having a pH of about 1.2.
[0033] Figure 2 is an image showing the results of evaluating the gelation pattern according to pH for the tablet of Example 1.
[0034] Figure 3 is an image showing the results of evaluating the dissolution pattern over time for the tablets of examples and comparative examples.
[0035] Figure 4 is a graph showing the results of evaluating the dissolution profile of anhydrous sodium sulfate for the tablets of examples and comparative examples.
[0036] Figure 5 is a schematic diagram showing the participation and treatment status of clinical trial subjects.
[0037] Hereinafter, the intent, function, and effects of the present invention will be described in detail through embodiments of the present invention and specific examples thereof. However, the following examples are provided as examples to aid understanding of the present invention and do not define or limit the scope of the invention.
[0038] Terms or words used in this specification and claims should not be interpreted as limited to their usual or dictionary meanings, but should be interpreted as meanings and concepts that conform to the technical idea of the present invention, based on the principle that the inventor can appropriately define the concept of the term to explain his or her own invention in the best way.
[0039] Accordingly, the configuration of the embodiments described in this specification is only one of the most preferred embodiments of the present invention and does not represent all of the technical ideas of the present invention, so it should be understood that various equivalents and modified examples that can replace them may exist at the time of filing this application.
[0040] In this specification, singular expressions include plural expressions unless the context clearly indicates otherwise.
[0041] When a part in this specification is said to “comprise” a certain component, this does not exclude other components unless specifically stated to the contrary, but rather means that other components may be included. Thus, for example, a composition comprising compound A may include compounds other than A. However, the term “comprise” also encompasses, as a specific embodiment thereof, the more restrictive meanings of “consisting essentially / essentially of” and “consisting of,” so that, for example, “a composition comprising compound A” may also consist (essentially / essentially) of compound A.
[0042] In this connection, it should be understood that terms such as “have” or “have” as used herein are intended to specify the presence of a feature, number, step, component, or combination thereof, but do not preclude the possibility of the presence or addition of one or more other features, numbers, steps, components, or combinations thereof.
[0043] When it is said in this specification that any element is located “on” another element, this includes not only cases where such element is in contact with the other element, but also cases where another element or material exists between the two elements.
[0044] Where an amount, concentration, or other value or parameter is given herein as a range, a preferred range, or an enumeration of an upper preferred value and a lower preferred value, this should be understood to specifically disclose any range that can be formed by any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether the range is separately disclosed. Where a range of numerical values is recited herein, unless otherwise stated, e.g., there is no limiting term such as greater than, less than, etc., the range is intended to include the endpoint values and all integers and fractions within the range. The scope of the present invention is not intended to be limited to the specific values recited when defining a range.
[0045] The present invention relates to a colon laxative tablet, which may include a tablet comprising an osmotic substance, simethicone, and a water-soluble binder; and / or a gel-forming coating layer formed on the tablet and comprising an alginate as a main component; wherein the osmotic substance may include at least one selected from the group consisting of anhydrous sodium sulfate, potassium sulfate, anhydrous magnesium sulfate, sodium sulfate hydrate, magnesium sulfate hydrate, sodium picosulfate hydrate, light magnesium oxide, citric acid, polyethylene glycol, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate, sodium bicarbonate, anhydrous sodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate, magnesium oxide, and potassium sulfate; and may include at least 50 wt% of the alginate based on the total weight of the gel-forming coating layer.
[0046] In one embodiment, the gel-forming coating layer comprising alginate as a main component may comprise alginate in an amount of at least 60 wt%, at least 70 wt%, at least 80 wt%, at least 90 wt%, at least 95 wt%, at least 96 wt%, at least 97 wt%, at least 98 wt%, or at least 99 wt% based on the total weight of the gel-forming coating layer.
[0047] In one embodiment, the alginate may be included in an amount of 0.1 to 20 parts by weight per 100 parts by weight of the osmotic material. In another embodiment, the alginate may be included in an amount of 0.2 parts by weight or more, 0.3 parts by weight or more, 0.4 parts by weight or more, 0.5 parts by weight or more, 0.6 parts by weight or more, 0.7 parts by weight or more, 0.8 parts by weight or more, 0.9 parts by weight or more, 1.0 parts by weight or more, 1.1 parts by weight or more, 1.2 parts by weight or more, 1.3 parts by weight or more, 1.4 parts by weight or more, 1.5 parts by weight or more, 2 parts by weight or more, 2.5 parts by weight or more, 3 parts by weight or more, 3.5 parts by weight or more, 4 parts by weight or more, or 4.5 parts by weight or more, or 18 parts by weight or less, 16 parts by weight or less, 14 parts by weight or less, 12 parts by weight or less, 10 parts by weight or less, 8 parts by weight or less, or 6 parts by weight or less, based on 100 parts by weight of the osmotic substance. The colon laxative tablet of the present invention can form a gel-forming coating layer uniformly with an appropriate thickness on the tablet by including alginate as described above.
[0048] In one embodiment, the thickness of the gel-forming coating layer can be in the range of 0.001 mm to 1 mm. In another embodiment, the thickness of the gel-forming coating layer can be 0.005 mm or more, 0.01 mm or more, 0.02 mm or more, 0.03 mm or more, 0.04 mm or more, 0.05 mm or more, 0.06 mm or more, 0.07 mm or more, 0.08 mm or more, or 0.09 mm or more, or 0.9 mm or less, 0.8 mm or less, 0.7 mm or less, 0.6 mm or less, 0.5 mm or less, 0.4 mm or less, 0.3 mm or less, or 0.2 mm or less.
[0049] The colonic laxative tablet of the present invention has an excellent intestinal cleansing effect by introducing a gel-forming coating layer on the tablet as described above, and can prevent damage to the gastric mucosa due to physical collision between the tablet and the gastric mucosa.
[0050] In one embodiment, the osmotic agent may include anhydrous sodium sulfate, potassium sulfate, and anhydrous magnesium sulfate.
[0051] In one embodiment, the osmotic substance may comprise 60 to 90 parts by weight of anhydrous sodium sulfate, 5 to 25 parts by weight of potassium sulfate, and / or 1 to 15 parts by weight of anhydrous magnesium sulfate, relative to 100 parts by weight of the osmotic substance. In another embodiment, the osmotic substance may comprise at least 65 parts by weight, at least 70 parts by weight, or at least 75 parts by weight of anhydrous sodium sulfate, or at most 85 parts by weight, or at most 80 parts by weight. In yet another embodiment, the osmotic substance may comprise at least 7 parts by weight, at least 9 parts by weight, at least 11 parts by weight, or at least 13 parts by weight of potassium sulfate, or at most 23 parts by weight, at most 21 parts by weight, at most 19 parts by weight, at most 17 parts by weight, or at most 15 parts by weight. In another embodiment, the anhydrous magnesium sulfate may be included in an amount of 2 parts by weight or more, 3 parts by weight or more, 4 parts by weight or more, 5 parts by weight or more, or 6 parts by weight or more, or 14 parts by weight or less, 13 parts by weight or less, 12 parts by weight or less, 11 parts by weight or less, 10 parts by weight or less, 9 parts by weight or less, or 8 parts by weight or less, per 100 parts by weight of the osmotic substance.
[0052] The colonic laxative tablet of the present invention can have an excellent colon cleansing effect even with a small dosage by controlling the type and / or weight ratio of the osmotic substance as described above, thereby improving medication compliance. This effect can be further maximized by introducing simethicone and / or a water-soluble binder as described below.
[0053] In one embodiment, the colonic laxative tablet of the present invention may contain 0.1 to 2 parts by weight of simethicone and / or 0.5 to 20 parts by weight of a water-soluble binder, relative to 100 parts by weight of the osmotic substance. In another embodiment, the colonic laxative tablet of the present invention may contain 0.2 parts by weight or more, 0.3 parts by weight or more, 0.4 parts by weight or more, 0.5 parts by weight or more, 0.6 parts by weight or more, or 0.7 parts by weight or more, or 1.9 parts by weight or less, 1.8 parts by weight or less, 1.7 parts by weight or less, 1.6 parts by weight or less, 1.5 parts by weight or less, 1.4 parts by weight or less, 1.3 parts by weight or less, 1.2 parts by weight or less, 1.1 parts by weight or less, 1.0 parts by weight or less, or 0.9 parts by weight or less, relative to 100 parts by weight of the osmotic substance. In another embodiment, the colonic laxative tablet of the present invention may contain 1 part by weight or more, 1.5 parts by weight or more, or 2 parts by weight or more, or 18 parts by weight or less, 16 parts by weight or less, 14 parts by weight or less, or 12 parts by weight or less of a water-soluble binder per 100 parts by weight of the osmotic substance.
[0054] In one embodiment, the water-soluble binder may be at least one selected from the group consisting of copovidone, polyethylene glycol, and povidone, and from the viewpoint of improving the disintegration speed, copovidone or polyethylene glycol may be preferred, and polyethylene glycol may be more preferred.
[0055] In one embodiment, the weight average molecular weight of the polyethylene glycol may be in the range of 3000 to 10000 g / mol. In another embodiment, the weight average molecular weight of the polyethylene glycol may be 4000 g / mol or more, 5000 g / mol or more, 9000 g / mol or less, 8000 g / mol or less, or 7000 g / mol or less. By introducing polyethylene glycol having a weight average molecular weight within the above range, the disintegration rate may be further improved.
[0056] In one embodiment, the alginate may be at least one selected from the group consisting of sodium alginate, potassium alginate, and magnesium alginate, and may be preferably sodium alginate from the viewpoint of preventing damage to the gastric mucosa and enhancing the effect of improving the disintegration rate by gelling in the gastric environment without impairing the osmotic properties of the tablet. As used herein, the “gastric environment” may mean the gastric environment in a natural state and / or the gastric environment in a state where a large amount of water is introduced.
[0057] In one embodiment, the gel-forming coating layer may further comprise an adhesion improving agent.
[0058] In one embodiment, the adhesive improver may be at least one selected from the group consisting of polyvinyl alcohol-polyethylene glycol graft copolymer, hypromellose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyol, gelatin, carboxymethyl cellulose, and povidone.
[0059] In one embodiment, the gel-forming coating layer may further comprise a mucosal protective agent.
[0060] In one embodiment, the mucosal protective agent may be at least one selected from the group consisting of ecabet sodium hydrate, irsogladin maleate, and polarprezinc.
[0061] The colon laxative tablet of the present invention can further enhance the gastric mucosa protection effect by selectively including a mucosa protective agent in the gel-forming coating layer.
[0062] In one embodiment, the colon laxative tablet of the present invention may further include an adhesive improvement coating layer containing the adhesive improvement agent as a main component on the gel-forming coating layer.
[0063] In one embodiment, the adhesion improver may be included in an amount of at least 50 wt% based on the total weight of the adhesion improver coating layer. In another embodiment, the adhesion improver may be included in an amount of at least 60 wt%, at least 70 wt%, at least 80 wt%, or at least 90 wt% based on the total weight of the adhesion improver coating layer.
[0064] In one embodiment, the adhesion improver may be included in an amount of 0.1 to 20 parts by weight relative to 100 parts by weight of the osmotic substance. In another embodiment, the adhesion improver may be included in an amount of at least 0.2 parts by weight, at least 0.3 parts by weight, at least 0.4 parts by weight, at least 0.5 parts by weight, at least 0.6 parts by weight, at least 0.7 parts by weight, at least 0.8 parts by weight, at least 0.9 parts by weight, at least 1.0 parts by weight, at least 1.1 parts by weight, at least 1.2 parts by weight, at least 1.3 parts by weight, at least 1.4 parts by weight, at least 1.5 parts by weight, at least 1.6 parts by weight, at least 1.7 parts by weight, or at most 18 parts by weight, at most 16 parts by weight, at most 14 parts by weight, at most 12 parts by weight, at most 10 parts by weight, at most 8 parts by weight, at most 6 parts by weight, or at most 4 parts by weight relative to 100 parts by weight of the osmotic substance. The colon laxative tablet of the present invention further includes an adhesive improvement coating layer as described above, thereby masking an unpleasant taste or smell when taking the tablet and improving stickiness in the mouth, thereby further improving the convenience of taking the medication. This effect can be further maximized when the gel-forming coating layer does not include an adhesive improvement agent.
[0065] In one embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution having a pH of 2 or lower according to the second dissolution test method, the osmotic substance may be dissolved at 30 wt% or less within 5 minutes. In the present specification, the dissolution of a wt% of an osmotic substance may mean that a wt% of the total weight of the osmotic substance contained in the tablet is dissolved. In another embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution having a pH of 2 or lower according to the second dissolution test method, the osmotic substance may be dissolved at 29 wt% or less, 28 wt% or less, 27 wt% or less, 26 wt% or less, 25 wt% or less, 24 wt% or less, 23 wt% or less, 22 wt% or less, 21 wt% or less, 20 wt% or less, 19.5 wt% or less, 19 wt% or less, or 18.5 wt% or less, or may be dissolved at 1 wt% or more, 2 wt% or more, 3 wt% or more, 4 wt% or more, or 5 wt% or more within 5 minutes. In the present specification, the osmotic substance when evaluating the dissolution profile of an osmotic substance according to the second dissolution test method may be, for example, anhydrous sodium sulfate.
[0066] In one embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution having a pH of 3.5 to 5.5 according to the second dissolution test method, the osmotic substance can be dissolved by 30% or more by weight within 5 minutes. In another embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution of pH 2.5 to 5.5 according to the second dissolution test method, the osmotic substance may be dissolved by 35 wt% or more, 40 wt% or more, 45 wt% or more, 50 wt% or more, 55 wt% or more, 60 wt% or more, 65 wt% or more, 70 wt% or more, 75 wt% or more, or 80 wt% or more, or 95 wt% or less, 90 wt% or less, 85 wt% or less, 80 wt% or less, 75 wt% or less, 70 wt% or less, 65 wt% or less, 60 wt% or less, or 55 wt% or less.
[0067] In one embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution having a pH of 6 to 8.5 according to the second dissolution test method, the osmotic substance may be dissolved at a rate of 40 wt% or more within 5 minutes. In another embodiment, when evaluating the dissolution profile of an osmotic substance of a tablet in a solution having a pH of 6 to 8.5 according to the second dissolution test method, the osmotic substance may be dissolved at a rate of 45 wt% or more, 50 wt% or more, 55 wt% or more, 60 wt% or more, 65 wt% or more, 70 wt% or more, 75 wt% or more, 80 wt% or more, 85 wt% or more, or 90 wt% or less, or 99 wt% or less, 98 wt% or less, 95 wt% or less, 90 wt% or less, 85 wt% or less, or 80 wt% or less within 5 minutes.
[0068] In one embodiment, the colon laxative tablet of the present invention may be circular or rectangular, and from the viewpoint of convenience of taking the medication, it may be circular with a diameter of preferably 10 mm or less, more preferably 7 mm or less.
[0069] The present invention may also relate to a colon laxative comprising two or more packaging bags each containing two or more of the colon laxative tablets, and wherein the colon laxative tablets contained in one of the packaging bags are taken at a time.
[0070] In one embodiment, the total dosage of the colonic laxative may be 38 to 55 g. The total dosage of the colonic laxative herein may refer to the total amount of the colonic laxative taken on the day before and / or on the day of the colonoscopy. In another embodiment, the total dosage of the colonic laxative may be 39 g or more, 40 g or more, 41 g or more, or 42 g or more, or 54 g or less, 53 g or less, 52 g or less, 51 g or less, 50 g or less, 49 g or less, or 48 g or less.
[0071] In one embodiment, the number of colon laxative tablets per packaging bag may be 5 or more, 10 or more, 15 or more, 20 or more, 25 or more, 30 or more, or 35 or more, or 80 or less, 70 or less, 60 or less, 50 or less, 40 or less, 30 or less, 20 or less, or 10 or less, but is not limited thereto, and may be appropriately adjusted depending on the size of the tablet.
[0072] The convenience of taking the colon laxative of the present invention can be further improved by taking it through a packaging bag as described above.
[0073] The present invention may also relate to a pharmaceutical composition for a colon laxative, wherein the day before a colonoscopy, 160 colon laxative tablets according to the above and 425 ml of water are taken, and then 850 ml of water is taken twice in 425 ml portions, and on the day of the examination, the colon laxative tablets and water are taken repeatedly in the same manner as above, and the total dosage of the colon laxative is 38 to 55 g. The respective dosing times on the day before and the day of the examination can be selected in a known manner depending on the time of performing the colonoscopy.
[0074] The present invention may also relate to a pharmaceutical composition for a colonic laxative, wherein on the day of a colonoscopy, 160 colonic laxative tablets according to the above and 425 ml of water are taken, and then 850 ml of water is taken in two additional doses of 425 ml each, repeating this twice, and the total dosage of the colonic laxative is 38 to 55 g. The time periods for each of the two doses on the day of the examination may be selected in a known manner depending on the time of the colonoscopy.
[0075] Hereinafter, the present invention will be described in detail by way of examples to specifically illustrate the disclosure of the present invention and its intended functions and effects, as described above. However, these examples may be modified in various ways, and the scope of this specification is not construed as being limited to these examples. It is emphasized that these examples are provided to represent the present invention and to provide a more concrete explanation to those skilled in the art.
[0076] <Example 1>
[0077] Manufacturing of Najeong
[0078] Anhydrous sodium sulfate, potassium sulfate, anhydrous magnesium sulfate, and simethicone were mixed in a high-speed mixer, and then polyethylene glycol (PEG 6000) was further added and mixed. The mixed composition was then compressed into tablets using a rotary tablet press. The weight of each component contained in one tablet was as shown in Table 1 below.
[0079] Formation of coating layer I
[0080] Sodium alginate was completely dissolved in purified water to prepare a coating solution I. Next, the tablet and coating solution I were placed in a film coater and coated under the following conditions: exhaust temperature 40 to 60°C, coating pan 2 to 10 rpm, and film coating solution pump 20 to 80 rpm. The weight of sodium alginate contained in one tablet formed through this was as shown in Table 1 below.
[0081] Formation of coating layer II
[0082] Polyvinyl alcohol-polyethylene glycol graft copolymer was completely dissolved in purified water to prepare a coating solution II. Next, the sodium alginate-coated tablet and coating solution II were placed in a film coater and coated under the conditions of an exhaust temperature of 40 to 60°C, a coating pan of 2 to 10 rpm, and a film coating solution pump of 20 to 80 rpm to prepare tablets. The weight of the polyvinyl alcohol-polyethylene glycol graft copolymer contained in one tablet formed through this was as shown in Table 1 below.
[0083] How to take
[0084] It can be taken in either divided or undivided form.
[0085] i) Split dose
[0086] On the evening before the test, take 40 tablets / 1 pack*4 packs with 425 mL of water, then add 850 mL of water (425 mL, 2 times). On the morning of the test, repeat the dose as before the test.
[0087] ii) Non-split dosing
[0088] After taking this medicine (40 tablets / 1 pack*4 packs) and 425 mL of water, take an additional 850 mL of water (425 mL, 2 times). Repeat the dose on the day of the examination.
[0089] <Example 2>
[0090] Tablets were manufactured in the same manner as in Example 1, except that the composition and weight of the tablets were as shown in Table 1 below.
[0091] Meanwhile, the same method as Example 1 was used, except that 14 tablets were taken instead of 40 tablets / 1 pack*4 packs.
[0092] <Comparative Example 1>
[0093] Tablets were manufactured in the same manner as in Example 1, except that the coating layer I was not formed. The dosage method was also the same as in Example 1.
[0094] Comparative Example 2
[0095] Tablets were manufactured in the same manner as in Example 1, except that sodium alginate was introduced into the tablet. The dosage method was also the same as in Example 1.
[0096] <Comparative Example 3>
[0097] Tablets were manufactured in the same manner as in Example 1, except that polyprezinc was introduced instead of sodium alginate in coating layer I. The dosage method was also the same as in Example 1.
[0098] <Comparative Example 4>
[0099] Tablets were manufactured in the same manner as in Example 2, except that coating layer I was not introduced. The dosage method was also the same as in Example 2.
[0100]
[0101] The tablets of Example 1 were grouped into 1 tablet, 11 tablets, and 40 tablets, and each tablet was left in a 0.1 N HCl solution (pH approximately 1.2) at 25 to 30°C for 30 minutes, and then gelation was confirmed. As a result, as shown in Fig. 1, it was confirmed that the coating layer containing sodium alginate was gelled.
[0102] Meanwhile, the tablet of Example 1 was left in HCl solutions at 25-30℃ with pH 1.0, pH 2.0, and pH 3.0 for 30 minutes, and the gelation pattern according to pH was confirmed. As a result, as shown in Fig. 2, it was confirmed that gelation was maintained under all conditions of pH 1.0, 2.0, and 3.0. Through this, it can be expected that the coating layer containing sodium alginate reacts with gastric acid to form a gel, which is a physical defense factor, and that even if the pH in the stomach is slightly increased by ingesting it with a large amount of water, the gelation is maintained, thereby providing an excellent gastric mucosal protection effect.
[0103] <Evaluation Example 2. Dissolution Pattern>
[0104] The tablets of the examples and comparative examples were placed in 410 mL of purified water in a beaker at about 25 to 30°C, and the beaker was shaken at intervals of about 1 hour. Examples 1 and 2 had a faster initial dissolution rate relative to the tablet size as compared to Comparative Examples 1, 2, and 4, which included sodium alginate in the tablet or did not introduce it at all, due to the introduction of a coating layer containing sodium alginate, and the initial dissolution rate was similar to that of Comparative Example 3, which was coated with polar prezinc. Through this, it can be expected that in the examples, not only is sodium alginate gelled in the stomach, but it is also rapidly dissolved relative to the tablet size, so that the gastric mucosa protection effect is excellent (Fig. 3).
[0105] <Evaluation Example 3. Osmotic Pressure>
[0106] The osmotic pressure of the tablets of Examples and Comparative Examples was measured using Osmamat 3000 (manufacturer: gonolec), an analysis device, after manufacturing them according to the osmotic pressure measurement method in the general test methods of the Korean Pharmacopoeia. As a result, it was confirmed that there was no significant difference in the osmotic pressure between the Examples and Comparative Examples, as shown in Table 2 below. Through this, it was expected that even if a gel-forming coating layer was introduced, the intestinal cleansing effect due to osmotic pressure or the imbalance due to electrolytes would be low.
[0107]
[0108] <Evaluation Example 4. Dissolution Pattern of Anhydrous Sodium Sulfate>
[0109] The dissolution profiles of anhydrous sodium sulfate of the tablets of Example 1 and Comparative Example 1 were evaluated according to the second dissolution test method. Specifically, 900 ml of test solutions of pH 1.2 (0.1 N HCl), pH 4.0, and pH 6.8 were prepared, and the test solutions were placed together with the tablets in a dissolution test device (paddle method), and the dissolution profiles of anhydrous sodium sulfate were confirmed over time while stirring at a speed of approximately 50 rpm (at a temperature of 37±2°C). As a result, in the case of Example 1, less than 20% was eluted within 5 minutes at pH 1.2, more than 40% was eluted within 5 minutes at pH 4.0, and more than 60% was eluted within 5 minutes at pH 6.8, whereas in the case of Comparative Example 4, more than 20% by weight was eluted within 5 minutes at pH 1.2, less than 10% by weight was eluted within 5 minutes at pH 4.0, and less than 15% by weight was eluted within 5 minutes at pH 6.8. Through this, it can be expected that the tablet of Example 1 will have an excellent intestinal cleansing effect due to a fast dissolution rate of osmotic substances in the body (Figs. 4(a) to (c)).
[0110] <Evaluation Example 5. Clinical Trial Results>
[0111] (1) Indications
[0112] Bowel cleansing before colonoscopy
[0113] (2) Methodology
[0114] This clinical trial was designed as a prospective, randomized, single-blind, 3-treatment arm, parallel treatment group, active-controlled, multi-center study.
[0115] Subjects who met the selection criteria through the screening examination visit (V1) were assigned to the clinical trial drug (Test Group 1 (Example 1 split dose), Test Group 2 (Example 1 non-split dose), Control Group (Comparative Example 4 split dose)) through the randomization visit (V2), and took the drug according to the individual dosage regimen (non-split dose - 1 day / split dose - 2 days) before undergoing a colonoscopy visit (V3).
[0116] (3) Dosage and administration
[0117] < Test drug (Example 1) >
[0118] -Dosage [based on one colonoscopy]: 8 packets (40 tablets per packet)
[0119] -Dosage: Oral administration twice (the day before and on the day of the examination) or once (on the day of colonoscopy)
[0120] ·Test Group 1 (Example 1_Split Dosage): After taking 4 packets of this medicine and 425 mL of water, they took an additional 850 mL of water (2 doses of 425 mL). This process was repeated on the day before and on the day of the test.
[0121] · Test Group 2 (Example 1_Undivided Dosage): After taking 4 packets of this medicine and 425 mL of water, they took an additional 850 mL of water (2 doses of 425 mL). This process was repeated 4-5 hours prior to the test.
[0122] < Control drug (Comparative Example 4) >
[0123] -Dosage [based on one colonoscopy]: 28 tablets
[0124] -Dosage: 2 times (the day before and the day of the test), administered orally
[0125] - After taking these 14 tablets and 425 mL of water, take an additional 850 mL of water (2 425 mL portions). The above process was repeated on the day before and on the day of the test.
[0126] (4) Treatment group assignment
[0127] Subjects were randomly assigned to the designated treatment group and administered the clinical trial drug. The number of subjects per treatment group was as shown in Figure 5.
[0128] (5) Statistical Methods
[0129] 1) Safety Analysis Group (Safety Set)
[0130] This refers to a group of subjects who were randomly assigned to this clinical trial, received the clinical trial drug at least once, and underwent safety-related follow-up observation.
[0131] 2) FA analysis set (Full Analysis set; FAS)
[0132] This refers to the group of subjects who were randomly assigned to this clinical trial, administered the investigational drug at least once, and had at least one efficacy evaluation measured after administration. In cases where colonoscopy was not performed due to unclean rectal discharge or adverse reactions caused by the administration of the investigational drug despite taking the investigational drug (bowel cleansing agent), the segment was evaluated as 'unsuccessful cleansing' on the Harefield cleansing scale when evaluating efficacy variables related to bowel cleansing and analyzed. In addition, in cases where colonoscopy was not completed due to poor bowel cleansing despite taking the investigational drug (bowel cleansing agent), the segment was evaluated as 0 points and analyzed as 'unsuccessful cleansing' on the Harefield cleansing scale when evaluating efficacy variables.
[0133] 3) PP1 analysis group (Principal Efficacy analysis set)
[0134] This refers to the group of subjects who received the investigational drug after randomization and underwent at least one efficacy evaluation, free of any major protocol violations (violations of inclusion / exclusion criteria, compliance violations, etc.). Compliance was based on an 80% threshold. Among the inclusion / exclusion criteria, violations of BMI or pregnancy test-related matters, which were deemed unlikely to interfere with the efficacy evaluation, were not excluded from the evaluation.
[0135] 4) PP2 analysis group
[0136] PP1 refers to the group of subjects who completed the clinical trial without any major violations.
[0137] Statistical analysis
[0138] The validity evaluation targets the FAS, PP1, and PP2 groups, and the safety evaluation targets the Safety group.
[0139] The principal efficacy analysis set is the PP1 group.
[0140] Missing values are not replaced with other values.
[0141] For descriptive statistics, the basic principles are mean, standard deviation, median, minimum and maximum values for continuous data, and frequency and proportion for categorical data, with more detailed data presented when necessary.
[0142] All statistical analyses except for non-inferiority evaluation are based on two-sided tests at a significance level of 0.05.
[0143] In the primary validity assessment, a gatekeeping method is applied to control the significance level at 5% or less. If hypothesis 1 confirms that test group 1 is non-inferior to the control group, hypothesis 2 is tested without further significance level adjustment.
[0144] (6) Discussion and overall conclusion
[0145] 1) Foam removal ability
[0146] The foam scores evaluated using colonoscopy with cleanliness did not show statistically significant differences between test groups 1 and 2 and the control group in both the total score and the scores for each compartment, regardless of whether the evaluator (validity assessment committee or colonoscopist) was present.
[0147] Since it has already been confirmed that simethicone contained in the control drug removes foam in the intestines, It was also determined that test groups 1 and 2 could help secure a clear view during colonoscopy by removing foam in the intestine.
[0148] 2) Subjective satisfaction with taking the medication
[0149] Subjective satisfaction with the medication, as assessed by the subjects, did not differ significantly between treatment groups. Therefore, it was determined that experimental groups 1 and 2 did not impair subjective satisfaction with the medication compared to the control group.
[0150] 3) Colonoscopy quality assessment
[0151] Since the quality of colonoscopy performance in all treatment groups achieved the previously recommended level goals, the quality of colonoscopy performed in this clinical trial was judged to be very good.
[0152] 4) Incidence of acute gastric mucosal damage due to drugs
[0153] Although lower outcomes were observed in the test group compared to the control group, the incidence of drug-induced acute gastric mucosal injury was not statistically significant between treatment groups. However, the proportion of subjects with a high drug-related association (acute injury score of 8 or higher) was lower in test group 1 compared to the control group, and this difference was statistically significant.
[0154] In previous studies evaluating acute gastric mucosal damage, independent evaluators determined the final causality with the drug after scoring according to evaluation criteria. However, in this trial, the evaluation was based solely on the score according to the evaluation criteria. Furthermore, since an upper endoscopy was not performed before administration of the clinical trial drug in this trial, the baseline degree of gastric damage could not be confirmed, and considering the bias of the evaluator's subjective assessment, the proportion of subjects with a highly related drug, defined as an acute damage score of 8 or higher, is considered a more clinically significant variable for comparing differences between treatment groups. Consequently, it is believed that the experimental drug component, sodium alginate, alleviated acute gastric mucosal damage.
[0155] 5) Safety
[0156] ① Abnormal cases
[0157] No deaths were reported, and only one serious adverse event, not causally related to the clinical trial drug, was reported. Only one adverse drug reaction was reported as the cause of discontinuation from the clinical trial.
[0158] Considering the occurrence status of adverse events ((1) abdominal distension, (2) nausea, (3) vomiting, (4) abdominal pain) that were scheduled to be collected in advance for the evaluation of adverse events, adverse drug reactions, and tolerability, including the occurrence status of serious adverse events and adverse events leading to withdrawal, the safety profiles of test groups 1 and 2 were similar to those of the control group, and the safety profiles were judged to be good.
[0159] ② Laboratory test results
[0160] It is well known that bowel preparations can cause temporary fluctuations in hematology and blood chemistry tests. This is particularly important because electrolyte fluctuations can trigger or worsen arrhythmias and seizures.
[0161] A comparison was conducted between groups regarding normal / abnormal changes in hematology and blood chemistry test items before administration (V2) and after administration (V3). As a result, there was no significant difference between groups in all test items, and no clinically significant abnormalities in laboratory test values were reported.
[0162] Although the temporal changes in some hematology and blood chemistry test items were statistically significant, most were judged to reflect physiological changes consistent with the temporary fluid loss and hemoconcentration caused by diarrhea, which is a pharmacological action of the bowel cleanser. In addition, considering that most of the significant changes in the average test values over time were reversible changes that normalized and the magnitude of the changes was minimal, the clinical significance of the changes in the average test values of the hematology and blood chemistry test items was judged to be small.
[0163] ③ Vital signs, physical examination, and electrocardiogram findings
[0164] The mean change over time in vital signs compared to before administration of the investigational drug showed no significant difference between treatment groups for all vital signs evaluation items, and the within-group change in vital signs on the day of colonoscopy (decrease in systolic and diastolic blood pressure, increase in pulse rate, decrease in weight, and decrease in body mass index) over time after administration of the investigational drug was estimated to be a finding consistent with a decrease in body fluid.
[0165] No subjects were reported to have clinically significant abnormal findings on physical examination or electrocardiogram.
[0166] 6) Conclusion
[0167] When comprehensively evaluating the above, test groups 1 and 2 demonstrated non-inferiority compared to the control group in terms of cleansing quality, as measured by the Harefield scale. Furthermore, they removed intestinal foam at a similar level to the control group, helping to secure a clear view during colonoscopy. Furthermore, they demonstrated similar efficacy to Orapang tablets in terms of ease of use and satisfaction, subjective evaluations by users of colon cleansing agents.
[0168] In addition, as a result of analyzing and evaluating the evaluation of adverse events that occurred, systematic collection using questionnaires, evaluation of vital signs and physical examination findings, and laboratory test results such as hematology and blood chemistry tests and urinalysis, both test groups 1 and 2 showed no difference in safety from the control group, and it was confirmed to be a bowel cleansing agent with a good safety profile.
[0169] Considering all of the above results, test groups 1 and 2 were judged to be non-inferior to the control group in terms of colon cleansing effect for colonoscopy, while also being good in terms of safety.
[0170] Specific results are shown in Tables 3 to 8 below.
[0171]
[0172] Table 3 shows the percentage of subjects evaluated by the evaluation committee, classified into four levels: A, B, C, and D on the Harefield Purity Scale.
[0173] In this specification, N refers to the number of subjects, A refers to cases where all of the segments have scores of 3 or 4, B refers to cases where at least one segment has a score of 2, C refers to cases where at least one segment has a score of 1, and D refers to cases where at least one segment has a score of 0. In this specification, segment refers to the rectum, sigmoid colon, descending colon, transverse colon, and ascending colon. Here, the HAREFIELD 5-level bowel preparation scale score for each segment was scored according to the following criteria.
[0174] -0 points: Irremovable, heavy, hard stools
[0175] -1 point: Semi-solid, only partially removable stools
[0176] -2 points: brown liquid removable semi-solid stools
[0177] -3 points: clear liquid
[0178] -4 points: empty and clean
[0179]
[0180] Table 4 shows the proportion of subjects who were rated as A or B, or C or D on the Harefield cleanliness scale as assessed by colonoscopists.
[0181]
[0182] Table 5 shows the percentage of subjects evaluated by colonoscopists in four stages (A, B, C, and D) on the Harefield cleanliness scale.
[0183]
[0184] Table 6 shows the proportion of subjects who were evaluated by classifying the taste felt after oral administration of the clinical trial drug into four levels: ‘no taste or good taste’, ‘bad taste but tolerable’, ‘difficult to tolerate’, and ‘unable to eat’.
[0185]
[0186] Table 7 shows information on subjects who developed drug-induced acute gastric mucosal damage, as assessed by the practitioner during gastroscopy, after oral administration of the investigational drug among subjects who tested negative for H. pylori (score: 3 points or overall NA).
[0187]
[0188] Table 8 shows the results of a comparison between groups of subjects with an acute injury score of 8 or more among all subjects.
Claims
1. A tablet containing an osmotic agent, simethicone and a water-soluble binder; and A gel-forming coating layer comprising alginate as a main component formed on the above-mentioned surface; The above osmotic substance includes at least one selected from the group consisting of anhydrous sodium sulfate, potassium sulfate, anhydrous magnesium sulfate, sodium sulfate hydrate, magnesium sulfate hydrate, sodium picosulfate hydrate, light magnesium oxide, citric acid, polyethylene glycol, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate, sodium bicarbonate, sodium bicarbonate anhydrous, sodium dihydrogen phosphate monohydrate, magnesium oxide and potassium sulfate. A colon laxative tablet comprising at least 50 wt% of the above alginate based on the total weight of the gel-forming coating layer.
2. A laxative tablet according to claim 1, wherein the osmotic substance comprises anhydrous sodium sulfate, potassium sulfate and anhydrous magnesium sulfate.
3. A colon laxative tablet comprising 60 to 90 parts by weight of anhydrous sodium sulfate, 5 to 25 parts by weight of potassium sulfate, and 1 to 15 parts by weight of anhydrous magnesium sulfate, per 100 parts by weight of the osmotic substance in the second paragraph.
4. A colonic laxative tablet comprising 0.1 to 2 parts by weight of simethicone and 0.5 to 20 parts by weight of a water-soluble binder per 100 parts by weight of the osmotic substance in the first paragraph.
5. A laxative tablet according to claim 1, wherein the water-soluble binder is at least one selected from the group consisting of copovidone, polyethylene glycol, and povidone.
6. A laxative tablet according to claim 1, wherein the alginate is at least one selected from the group consisting of sodium alginate, potassium alginate, and magnesium alginate.
7. A laxative tablet according to claim 1, wherein the gel-forming coating layer further comprises an adhesive improving agent.
8. A laxative tablet according to claim 7, wherein the adhesive improving agent is at least one selected from the group consisting of polyvinyl alcohol-polyethylene glycol graft copolymer, hypromellose, hydroxypropyl cellulose, hydroxyethyl cellulose, polyol, gelatin, carboxymethyl cellulose, and povidone.
9. A colon laxative tablet according to claim 1, wherein the gel-forming coating layer further comprises a mucosal protective agent.
10. A colon laxative tablet in claim 9, wherein the mucosal protective agent is at least one selected from the group consisting of ecabet sodium hydrate, irsogladin maleate, and polarprezinc.
11. A colon laxative tablet further comprising an adhesive improvement coating layer containing an adhesive improvement agent as a main component on the gel-forming coating layer in the first paragraph.
12. A colon laxative tablet comprising the adhesive improving agent in an amount of 50 wt% or more based on the total weight of the adhesive improving coating layer in accordance with claim 11.
13. A colon laxative tablet, wherein, in the first paragraph, when evaluating the dissolution pattern of an osmotic substance of a tablet in a solution having a pH of 2 or lower according to the second dissolution test method, the osmotic substance is dissolved at 30% by weight or less within 5 minutes.
14. A colon laxative tablet in which, when evaluating the dissolution pattern of an osmotic substance of a tablet in a solution having a pH of 3.5 to 5.5 according to the second dissolution test method in paragraph 1, the osmotic substance is dissolved by 30% or more by weight within 5 minutes.
15. A colon laxative tablet in which, when evaluating the dissolution pattern of an osmotic substance of a tablet in a solution of pH 6 to 8.5 according to the second dissolution test method in paragraph 1, the osmotic substance is dissolved by 40% or more by weight within 5 minutes.
16. A colonic laxative comprising two or more packaging bags containing two or more colonic laxative tablets according to Article 1, and taking the colonic laxative tablets contained in one of the packaging bags at a time.
17. A pharmaceutical composition for colon laxative, wherein the colon laxative tablets according to Article 1 are taken the day before a colonoscopy examination, 160 tablets and 425 ml of water are taken, and then 850 ml of water is taken twice in 425 ml portions each, and on the day of the examination, the colon laxative tablets and water are taken repeatedly in the same manner as above, and the total dosage of the colon laxative is 38 to 55 g.
18. A pharmaceutical composition for colon laxative, wherein on the day of colonoscopy, 160 colon laxative tablets according to Article 1 and 425 ml of water are taken, and then 850 ml of water is taken in two additional doses of 425 ml each, repeating this twice, and the total dosage of colon laxative is 38 to 55 g.
Citation Information
Patent Citations
Enteric Coated Tablet
KR1020150118160A
Degas chamber for secondary cell and system having the same
KR1020200118992A
Pulse amplitude modulation transmitter / receiver and method for limit transition level thereof
KR102717159B1
KR20190142620A
Cited By
Formulation with simethicone, polyethylene glycol and hydroxyethylcellulose
GR1011186B
